<unk>  is an antineoplastic agent that is FDA approved for the treatment of adult patients with chronic, accelerated, or blast phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) with resistance or intolerance to prior therapy.   Common adverse reactions include diarrhea , nausea, thrombocytopenia, vomiting, abdominal pain, rash, anemia, pyrexia, fatigue and Serious adverse reactions  include anaphylactic shock , myelosuppression, gastrointestinal toxicity (diarrhea), fluid retention, hepatotoxicity and rash..
Bosutinib
Ibrutinib
Acalabrutinib
Afatinib
Ceritinib
Ruxolitinib
Neratinib
Sunitinib